Bleselumab - Wikipedia

Bleselumab
Monoclonal antibody
Type	Whole antibody
Source	Human
Target	CD40
Clinical data
Other names	ASKP1240
ATC code	none
Identifiers
CAS Number	1453067-91-8
ChemSpider	none
UNII	AS3AZ5R46K
KEGG	D11357
Chemical and physical data
Formula	C₆₄₁₂H₉₉₀₆N₁₆₉₀O₂₀₁₈S₃₈
Molar mass	144175.87g·mol⁻¹

Bleselumab(INN;^[1]development codeASKP1240) is a human monoclonal antibody designed for the prevention oforgan transplant rejection.^[2]^[3]

This drug was developed by Kyowa Kirin Pharmaceutical Development Inc.^[4]

References

[edit]

^World Health Organization(2015)."International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 113"(PDF).WHO Drug Information.29(2).
^Wojciechowski D, Vincenti F (November 2016). "Current status of costimulatory blockade in renal transplantation".Current Opinion in Nephrology and Hypertension.25(6): 583–590.doi:10.1097/MNH.0000000000000268.PMID 27517137.S2CID 4379881.
^Malvezzi P, Jouve T, Rostaing L (November 2016)."Costimulation Blockade in Kidney Transplantation: An Update".Transplantation.100(11): 2315–2323.doi:10.1097/TP.0000000000001344.PMC5084636.PMID 27472094.
^Statement On A Nonproprietary Name Adopted By The USAN Council - Bleselumab,American Medical Association.

Monoclonal antibodiesfor theimmune system

Immune system

Human	Immunosuppression:Abrilumab Adalimumab^# Anifrolumab Atorolimumab Avelumab Avdoralimab Belimumab Bleselumab Brodalumab Camidanlumab tesirine Carlumab Cemiplimab Dupilumab Eldelumab Emapalumab Fresolimumab Golimumab Ianalumab^† Lanadelumab Lenzilumab Lerdelimumab Lirentelimab Lirilumab Mavrilimumab Metelimumab Morolimumab Namilumab Oleclumab Oxelumab§ Pamrevlumab Placulumab Relatlimab^† Sarilumab Sifalimumab Tabalumab Tezepelumab Ulocuplumab Varlilumab Immune activation:Ipilimumab Durvalumab Nivolumab Tremelimumab Urelumab Other:Bertilimumab Ontamalimab Zanolimumab Combination:Nivolumab/relatlimab
Mouse	Afelimomab Elsilimomab Faralimomab Gavilimomab Inolimomab Maslimomab Nerelimomab Odulimomab Telimomab aritox Vepalimomab Zolimomab aritox
Chimeric	Andecaliximab^† Basiliximab Clenoliximab Galiximab Gomiliximab Infliximab Keliximab Lumiliximab Priliximab Teneliximab Vapaliximab
Humanized	Immunosuppressive:Apolizumab^§ Aselizumab Atezolizumab Benralizumab Camrelizumab^† Cedelizumab Certolizumab pegol Crizanlizumab Daclizumab Eculizumab Efalizumab^‡ Epratuzumab Erlizumab Etrolizumab^† Fontolizumab Frexalimab^† Inebilizumab Itolizumab Lampalizumab^† Letolizumab Ligelizumab^† Lulizumab pegol Mepolizumab Mogamulizumab Natalizumab Ocrelizumab Omalizumab Ozoralizumab Pascolizumab Pateclizumab Pembrolizumab Pexelizumab Pidilizumab Plozalizumab PRO 140^† Quilizumab Ravulizumab Reslizumab Retifanlimab Rontalizumab Rovelizumab Ruplizumab Samalizumab Satralizumab Siplizumab Spartalizumab^† Talizumab Teclistamab Teplizumab Tislelizumab Tocilizumab Toralizumab Tregalizumab Vatelizumab Vedolizumab Visilizumab Vobarilizumab TGN1412^§ Immune activation:Dostarlimab Other:Ibalizumab
Chimeric + humanized	Otelixizumab Rozanolixizumab Sutimlimab

Interleukin

Human	Bermekimab Brazikumab Briakinumab Canakinumab Fezakinumab Fletikumab Guselkumab Secukinumab Sirukumab Tralokinumab Ustekinumab
Humanized	Anrukinzumab Bimekizumab Clazakizumab Gevokizumab Ixekizumab Mirikizumab^† Lebrikizumab Olokizumab^† Perakizumab Risankizumab Spesolimab Tildrakizumab
Veterinary	Lokivetmab

Inflammatorylesions

Mouse	Besilesomab Fanolesomab^‡ Lemalesomab Sulesomab

^#WHO-EM
^‡Withdrawnfrom market
Clinical trials:
- ^†Phase III
- ^§Never to phase III

Thismonoclonal antibody–related article is astub.You can help Wikipedia byexpanding it.